MedTrace Logo

D-Serine Treatment of Negative Symptoms and Cognitive Deficits in Schizophrenia

NCT00237809 · Status: COMPLETED · Phase: PHASE3 · Type: INTERVENTIONAL · Enrollment: 104

Last updated 2017-05-10

Study results available
· View outcomes & findings →

Summary

This study is based on the hypothesis that by increasing N-methyl-D-aspartic acid (NMDA) receptor function in the brain and thereby increasing the capacity of the brain to both form new connections and strengthen existing connections, schizophrenic patients may derive both greater and sustained benefit from cognitive retraining.

Conditions

Interventions

DRUG

D-serine

D-serine (30 mg/kg)

BEHAVIORAL

Cognitive Retraining (CRT)

Cognitive retraining therapy (CRT)

DRUG

Placebo

Placebo D-serine Drug

BEHAVIORAL

Cognitive Retraining Placebo

Cognitive retraining therapy (CRT) control

Sponsors & Collaborators

  • National Alliance for Research on Schizophrenia and Depression

    collaborator OTHER

  • Donaghue Medical Research Foundation

    collaborator OTHER

  • Yale University

    lead OTHER

Principal Investigators

  • Deepak C D'Souza, M.D. · Yale University

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
TRIPLE
Model
PARALLEL

Eligibility

Min Age
18 Years
Max Age
65 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2002-09-30
Primary Completion
2010-12-31
Completion
2012-09-30

Countries

  • United States

Study Locations

More Related Trials

Entities

Drugs
Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT00237809 on ClinicalTrials.gov